26th Apr 2012 17:38
26 April 2012
LSE: VER
NOTICE OF CHANGE OF REGISTERED OFFICE ADDRESS
Vernalis plc (LSE: VER) announces it has changed its registered office address to 100 Berkshire Place, Wharfedale Road, Winnersh, Berkshire RG41 5RD
Enquiries:
Vernalis | +44 (0) 118 938 0015 |
Ian Garland, Chief Executive Officer David Mackney, Chief Financial Officer
| |
Nomura Code Securities | +44 (0) 20 7776 1200 |
Jonathan Senior, Giles Balleny
| |
Brunswick Group | +44 (0) 20 7404 5959 |
Jon Coles, Kristin Shine
| |
Taylor Rafferty | +44 (0) 20 7614 2900 |
Rob Newman, Faisal Kanth
|
Notes to Editors
About Vernalis
Vernalis is a revenue generating development stage pharmaceutical company with significant expertise in drug development. The Group has one marketed product, frovatriptan for the acute treatment of migraine, an exclusive licensing agreement to develop and commercialise multiple novel products focussed on the US prescription cough/cold market as well as eight programmes in its NCE development pipeline. Vernalis has significant expertise in fragment and structure based drug discovery which it leverages to enter into collaborations with larger pharmaceutical companies. The Company's technologies, capabilities and products are endorsed by collaborations with Endo, Genentech, GSK, Lundbeck, Menarini, Novartis, Servier and Tris.
For further information about Vernalis, please visit www.vernalis.com
Related Shares:
Vernalis PLC